Cancer Screening Guidelines in the US, Taiwan, Japan and Korea, Side by Side
The US, Taiwan, Japan and Korea all screen for colorectal, breast, cervical and lung cancer, at different ages and with different tests. Japan and Korea also screen the stomach every 2 years, from 50 and 40. Korea scans the liver every 6 months in adults 40 and over with hepatitis B or C, and Taiwan examines betel-nut chewers' and smokers' mouths every 2 years. None of the three Asian programmes screens for prostate or thyroid cancer.
All four countries screen healthy adults for colorectal, breast, cervical and lung cancer, at different ages and intervals. They part ways on three organs. Japan and Korea look at the stomach every 2 years. Korea scans the liver every 6 months in adults 40 and over who carry hepatitis B or C or have cirrhosis. Taiwan examines the mouths of betel-nut chewers and smokers every 2 years. None of the three Asian national programmes screens for prostate or thyroid cancer.
This page sets the four programmes side by side, cited to each government's own documents as of October 2026. It then explains why the lists differ and which Asian check-up extras have evidence behind them for a US reader.
What does each country's national programme screen for?
Each row gives age, interval and test. Unless a bracket names another source, Japan's rows come from the MHLW guideline (revised 7 October 2026), Korea's from the National Cancer Screening Program (NCSP) paper of 2025, and Taiwan's from the HPA. "Not in the programme" means the cancer is absent from that country's official list.
Colorectal cancer
| Country | Programme |
|---|---|
| United States | 45–75: FIT every year, stool DNA-FIT every 1–3 years, CT colonography every 5 years, or colonoscopy every 10 years (USPSTF 2021). The ACS 2026 update also starts at 45 |
| Taiwan | 45–74: FIT every 2 years. 40–44 if a parent, child or sibling had colorectal cancer |
| Japan | 40 and over, priority 40–69: FIT every year |
| Korea | 50 and over: FIT every year, colonoscopy if positive |
Breast cancer
| Country | Programme |
|---|---|
| United States | Women 40–74: mammogram every 2 years (USPSTF 2024) |
| Taiwan | Women 40–74: mammogram every 2 years |
| Japan | Women 40 and over, priority 40–69: mammogram every 2 years |
| Korea | Women 40 and over: mammogram every 2 years |
Cervical cancer
| Country | Programme |
|---|---|
| United States | 21–29: Pap every 3 years. 30–65: Pap every 3 years, HPV test every 5 years, or both every 5 years (USPSTF 2018, update in progress). The ACS prefers an HPV test every 5 years from 25 to 65 (revised Dec 2025) |
| Taiwan | 25–29: Pap every 3 years. 30 and over: Pap subsidised yearly, at least every 3 years advised. An HPV test is added at 35, 45 and 65 (MOHW Dec 2024) |
| Japan | 20 and over, priority 20–69: Pap every 2 years. 30 and over, priority 30–60: HPV test alone every 5 years, where the city offers it |
| Korea | Women 20 and over: Pap every 2 years |
Lung cancer
| Country | Programme |
|---|---|
| United States | 50–80 with 20 or more pack-years, still smoking or quit within 15 years: low-dose CT every year (USPSTF 2021) |
| Taiwan | Low-dose CT every 2 years for men 45–74 or women 40–74 with a parent, child or sibling who had lung cancer; or for 50–74 with 20 or more pack-years who still smoke and are willing to quit, or quit within 15 years (MOHW Dec 2024) |
| Japan | 40 and over, priority 40–69: chest X-ray with a questionnaire every year |
| Korea | 54–74 with 30 or more pack-years, still smoking or quit within 15 years: low-dose CT every 2 years |
Stomach cancer
| Country | Programme |
|---|---|
| United States | No USPSTF recommendation. Endoscopy to be considered for defined high-risk groups (AGA 2025) |
| Taiwan | No endoscopy programme. One H. pylori stool antigen test in a lifetime at 45–74, from 2026 (MOHW Jan 2026) |
| Japan | 50 and over, priority 50–69: gastroscopy or barium X-ray every 2 years. For now the X-ray may cover people from 40 and be offered yearly |
| Korea | 40 and over: gastroscopy every 2 years, or a barium upper GI series selectively |
Liver cancer
| Country | Programme |
|---|---|
| United States | Hepatitis C blood test once at 18–79. Hepatitis B test for higher-risk people, such as those born where 2% or more carry it (USPSTF 2020). Ultrasound with AFP every 6 months for cirrhosis and some hepatitis B carriers (AASLD 2023) |
| Taiwan | Hepatitis B and C blood test once, for people born in 1986 or earlier, up to 79 (MOHW Nov 2025). If positive: liver blood tests and abdominal ultrasound every 3–6 months advised (HPA, 2024) |
| Japan | Hepatitis B and C blood tests offered by municipalities from 40 (MHLW fiscal 2024 report). No liver cancer screen in the national list |
| Korea | Hepatitis B test at 40 (NHIS). Hepatitis C antibody test at 56, from 2025 (KDCA). 40 and over with cirrhosis, hepatitis B or hepatitis C: ultrasound and AFP every 6 months |
Oral, prostate and thyroid cancer
| Country | Programme |
|---|---|
| United States | Oral: evidence insufficient for adults without symptoms (USPSTF 2013, grade I). Prostate: 55–69, PSA is an individual decision (grade C); 70 and over, recommends against (grade D) (USPSTF 2018, update in progress). Thyroid: recommends against screening adults without symptoms (USPSTF 2017, grade D) |
| Taiwan | Oral: 30 and over who chew betel nut, now or in the past, or smoke, oral exam every 2 years; Indigenous chewers from 18. Prostate: not in the programme, and the HPA says evidence that PSA lowers deaths is insufficient (HPA 2025). Thyroid: not in the programme |
| Japan | None of the three is in the programme |
| Korea | None of the three is in the programme |
Screenings you book with us are self-paid; Taiwan's National Health Insurance does not cover short-term visitors.
Where do the four programmes agree, and where do the tests differ?
The programmes differ in the first test, the starting age and the interval. Taiwan, Japan and Korea start colorectal screening with a stool test. The American Cancer Society's May 2026 update kept the US start at 45 and recommends blood-based tests only for people who decline or do not complete the preferred tests. For cervical screening, Korea still uses the Pap test while the others add or prefer HPV testing.
Lung screening differs most, because each country chose a different group: heavy smokers in the US and Korea, people with a family history in Taiwan whether or not they smoked, and everyone from 40 with a chest X-ray in Japan.
The trials favour CT over X-ray for heavy smokers. In the US National Lung Screening Trial of 53,454 high-risk people, three yearly low-dose CT scans cut lung cancer deaths by 20.0% compared with chest X-ray. In the US PLCO trial, four yearly chest X-rays did not lower lung cancer deaths compared with usual care (rate ratio 0.99). This article does not assess the evidence behind Japan's guideline. Taiwan's main evidence for its family-history group is the TALENT study of 12,011 never-smokers and light smokers, which measured how many cancers screening found, not deaths. See our low-dose lung CT page.
Why do Japan and Korea screen the stomach, and Taiwan does not?
Stomach cancer is far more common in Japan and Korea than in Taiwan or the US (rates in the table below). Korea has measured its own programme. A nested case-control study inside it drew on 16,584,283 adults aged 40 and over. People who had ever had a screening gastroscopy had 47% lower odds of dying of stomach cancer than people never screened (odds ratio 0.53). The barium upper GI series showed no such link (odds ratio 0.98). It was not a randomised trial.
Taiwan's health ministry states that about 80 to 90% of stomach cancers are caused by H. pylori infection. Since 1 January 2026, Taiwan has offered people 45 to 74 one H. pylori stool antigen test in a lifetime. Our H. pylori article covers the Matsu Islands study of mass H. pylori eradication in Taiwan.
The US has no population programme for the stomach. The American Gastroenterological Association's 2025 update says defined high-risk groups should be considered for screening, names endoscopy as the best test and calls H. pylori eradication essential. Our gastroscopy and colonoscopy page explains the procedure.
Why do Taiwan and Korea single out the liver?
Liver cancer is common in both, and the Health Promotion Administration states that about 80% of Taiwan's liver cancer patients have chronic hepatitis B or C. All four countries start with a blood test for the viruses. After a positive result, Korea scans adults 40 and over with cirrhosis, hepatitis B or C every 6 months, by ultrasound with an AFP blood test. Taiwan advises liver blood tests and abdominal ultrasound every 3 to 6 months. The US has no national programme for the scan, but the American Association for the Study of Liver Diseases recommends ultrasound with AFP every 6 months for cirrhosis and for hepatitis B carriers with added risk, such as men over 40 or women over 50 from countries where the virus is common. Japan has no liver cancer screen in its national list.
The evidence for the 6-month scan comes from people who already carry hepatitis B. A Shanghai trial of 18,816 people aged 35 to 59 with hepatitis B infection or chronic hepatitis found that screening every 6 months with AFP and ultrasound cut liver cancer deaths by 37%. It excluded people without liver disease, so the useful order is a blood test first and a scanning schedule only if it is positive. Our abdominal ultrasound page explains what the scan can and cannot see.
Why does Taiwan screen the mouth?
Oral cancer is far more common in Taiwan than in the other three countries (see table below), and Taiwan has screened betel-nut chewers and smokers since 2004. A 2017 evaluation covered 2,334,299 smokers and betel quid chewers. Before any adjustment, screened people had a 47% lower risk of dying of oral cancer than expected (relative risk 0.53). After adjusting for self-selection (people who attend differ from those who do not), the reduction was 26% (relative risk 0.74).
This is an observational result in a high-risk group, and the USPSTF finds the evidence insufficient for adults without symptoms. If you neither chew betel nut nor smoke, Taiwan's own programme would not screen you.
Why does no Asian national programme screen for prostate or thyroid cancer?
Japan's National Cancer Center says the state does not recommend screening outside its list of five, because benefit in reducing cancer deaths has not been established for the others. Taiwan's Health Promotion Administration states there is not yet enough evidence that PSA testing lowers prostate cancer deaths, and warns of overdiagnosis and overtreatment.
For prostate cancer, our prostate exam page compares the guidance. For thyroid cancer, the USPSTF recommends against screening adults without symptoms. Recorded thyroid cancer rates for both sexes are 32.0 per 100,000 in Korea, 17.43 in Taiwan, 10.7 in the US and 8.8 in Japan. Our article on overdiagnosis explains what happened when Korean clinics offered thyroid ultrasound alongside the national programme.
Which cancers are more common in each country?
The table shows new cases among men per 100,000, age-standardised to a world population, as each source prints them.
| Cancer, men | United States | Taiwan | Japan | Korea | Who screens for it |
|---|---|---|---|---|---|
| Stomach | 5.1 | 10.51 | 48.2 | 33.9 | Japan and Korea; Taiwan tests for H. pylori |
| Liver | 8.3 | 31.13 | 14.8 | 20.6 | Korea, in carriers and cirrhosis |
| Nasopharynx | 0.57 | 5.90 | 0.50 | 0.91 | None of the four |
| Lip and oral cavity | 6.5 | 27.55 | 4.7 | 2.4 | Taiwan, in chewers and smokers |
Taiwan's figures, including its thyroid rate above, are its cancer registry's 2023 age-standardised rates as published. Taiwan is not listed separately in GLOBOCAN, so the other columns are GLOBOCAN 2024 estimates. Read the gaps, not the decimals.
Nasopharyngeal cancer shows that a high rate alone does not create a programme. Taiwanese men's rate is over six times that of the other three countries, and Taiwan recorded 1,456 new cases in 2023, yet none of the four lists screens for it. A Hong Kong study tested 20,174 people for Epstein-Barr virus (EBV) DNA in the blood. Of 34 cancers found after persistently positive results, 71% were at stage I or II, against 20% in an earlier group of patients. It did not compare deaths with an unscreened group.
Why does a private check-up include tests no national programme pays for?
A national programme spends public money across a whole population, so it asks for proof that a test reduces deaths. A private check-up sells what the buyer chooses. Japan's National Cancer Center states the programme rule plainly: screening should be certain to reduce cancer deaths, and its benefits should outweigh its harms. It names the tests private check-ups add, CT, PET and tumor markers, as useful for checking recurrence and spread but not recognised as cancer screening.
Programmes also screen by risk. Taiwan's oral exam requires betel-nut chewing or smoking, and Korea's liver scan requires hepatitis or cirrhosis. A check-up that offers the same test to everyone drops the risk filter that the programme's evidence depends on.
Which Asian extras should a US reader add, and which can they skip?
Start with what US guidelines recommend for your age and sex, then add an extra only if you belong to the risk group its evidence comes from.
| Extra | Evidence | Who it fits | Ours, with our price |
|---|---|---|---|
| Upper endoscopy (gastroscopy) | Korea: 47% lower odds of stomach cancer death after screening gastroscopy (case-control) | The AGA 2025 groups: immigrants from high-incidence regions, a first-degree relative with stomach cancer, hereditary syndromes | Upper Endoscopy & Colonoscopy at iHope Clinic, $499; Upper Endoscopy as an add-on, $250 |
| H. pylori test | Taiwan funds one test at 45–74 | The groups listed in our H. pylori article | H Pylori Breath Test at iHope Clinic, $75 |
| Hepatitis B and C blood test | USPSTF grade B for both | Hepatitis C: every adult 18–79, once. Hepatitis B: if born where 2% or more carry it | Included in Vital ($699), Premium ($1,699) and Advanced ($3,499); Comprehensive Blood Work Panel add-on, $249 |
| Liver ultrasound every 6 months | Shanghai trial in hepatitis B carriers: 37% fewer liver cancer deaths | Cirrhosis, or hepatitis B with added risk (AASLD). Not people without liver disease | iHope Clinic Abdomen Ultrasound, $95 |
| Low-dose lung CT for never-smokers | TALENT found more cancers with a family history; deaths not measured | Never-smokers with a first-degree relative with lung cancer, accepting that the effect on deaths is unproven | Low-Dose Lung CT included in Light ($1,399), Premium ($1,699), Complete ($1,699), Plus ($3,099) and Advanced ($3,499) |
| Oral cancer exam | Taiwan: 26% lower risk of oral cancer death (observational). USPSTF: insufficient | Betel-nut chewers and smokers | Not sold as a separate screen |
| Tumor marker panel | Not recognised as screening by Japan's National Cancer Center. The Hong Kong EBV DNA study measured detection, not deaths | Nobody, as a screen; see our tumor markers page | iHope Clinic Tumor Markers Panel, $245. It includes EBV VCA IgA, an antibody test, not the DNA test the Hong Kong study used |
| Thyroid ultrasound | USPSTF grade D; in no programme | Nobody without a lump or symptom; see our thyroid ultrasound page | Included in Light, Complete and Plus |
| PSA | USPSTF grade C at 55–69, D from 70 | Men 55–69 who have weighed benefits and harms with a doctor | Prostate Exam at iHope Clinic, $150 |
Prices are ours, in US dollars; package contents are on our health screening page. See what to add and what to skip and taking Taiwan results to your own doctor.
Sources
- US Preventive Services Task Force — A and B Recommendations (accessed 2026-10-18)
- US Preventive Services Task Force — Colorectal Cancer: Screening, 18 May 2021 (accessed 2026-10-18)
- American Cancer Society — Colorectal cancer screening guideline update, 27 May 2026 (accessed 2026-10-18)
- US Preventive Services Task Force — Breast Cancer: Screening, 30 April 2024 (accessed 2026-10-18)
- US Preventive Services Task Force — Cervical Cancer: Screening, 21 August 2018, update in progress (accessed 2026-10-18)
- American Cancer Society — Cervical cancer screening guidelines, last revised 4 December 2025 (accessed 2026-10-18)
- US Preventive Services Task Force — Lung Cancer: Screening, 9 March 2021 (accessed 2026-10-18)
- US Preventive Services Task Force — Prostate Cancer: Screening, 8 May 2018, update in progress (accessed 2026-10-18)
- US Preventive Services Task Force — Thyroid Cancer: Screening, 9 May 2017 (accessed 2026-10-18)
- US Preventive Services Task Force — Oral Cancer: Screening, 15 November 2013 (accessed 2026-10-18)
- US Preventive Services Task Force — Hepatitis B Virus Infection in Adolescents and Adults: Screening, 15 December 2020 (accessed 2026-10-18)
- US Preventive Services Task Force — Hepatitis C Virus Infection in Adolescents and Adults: Screening, 2 March 2020 (accessed 2026-10-18)
- Hepatology, 2023 — AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (accessed 2026-10-18)
- Gastroenterology, 2025 — AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review (accessed 2026-10-18)
- Health Promotion Administration, Taiwan — Cancer screening services (accessed 2026-10-18)
- Ministry of Health and Welfare, Taiwan — Expanded cancer screening from 2025, including HPV testing at 35, 45 and 65, 24 December 2024 (accessed 2026-10-18)
- Ministry of Health and Welfare, Taiwan — Publicly funded H. pylori testing from 2026, 27 January 2026 (accessed 2026-10-18)
- Health Promotion Administration, Taiwan — Adult preventive health services, including hepatitis B and C screening (accessed 2026-10-18)
- Ministry of Health and Welfare, Taiwan — One lifetime hepatitis B and C screening for people born in 1986 or earlier, 20 November 2025 (accessed 2026-10-18)
- Health Promotion Administration, Taiwan — 80% of liver cancer linked to hepatitis B and C: follow-up and treatment, 30 April 2024 (accessed 2026-10-18)
- Health Promotion Administration, Taiwan — Prostate cancer is common in men; see a doctor early for symptoms, 30 October 2025 (accessed 2026-10-18)
- Health Promotion Administration, Taiwan — Cancer Registry Annual Report 2023, December 2025 (accessed 2026-10-18)
- Ministry of Health, Labour and Welfare, Japan — Cancer screening: nationally recommended screenings and guideline, revised 7 October 2026 (accessed 2026-10-18)
- National Cancer Center Japan, Cancer Information Service — About cancer screening, updated 1 April 2026 (accessed 2026-10-18)
- Ministry of Health, Labour and Welfare, Japan — Community health and health promotion services report, fiscal 2024, including hepatitis virus screening, 17 March 2026 (accessed 2026-10-18)
- Journal of Preventive Medicine and Public Health, 2025 — Lee K, Suh M, Choi KS. Current Status of the National Cancer Screening Program in Korea (accessed 2026-10-18)
- National Health Insurance Service, Korea — General health screening items (accessed 2026-10-18)
- Korea.kr, Korea Disease Control and Prevention Agency — Hepatitis C added to national health screening at age 56, 21 January 2025 (accessed 2026-10-18)
- International Agency for Research on Cancer — GLOBOCAN 2024, Cancer Today: United States, men; thyroid, both sexes (accessed 2026-10-18)
- International Agency for Research on Cancer — GLOBOCAN 2024, Cancer Today: Japan, men; thyroid, both sexes (accessed 2026-10-18)
- International Agency for Research on Cancer — GLOBOCAN 2024, Cancer Today: Republic of Korea, men; thyroid, both sexes (accessed 2026-10-18)
- Gastroenterology, 2017 — Jun JK et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality (accessed 2026-10-18)
- Journal of Cancer Research and Clinical Oncology, 2004 — Zhang BH et al. Randomized controlled trial of screening for hepatocellular carcinoma (accessed 2026-10-18)
- Cancer, 2017 — Chuang SL et al. Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers (accessed 2026-10-18)
- New England Journal of Medicine, 2011 — National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening (accessed 2026-10-18)
- JAMA, 2011 — Oken MM et al. Screening by chest radiograph and lung cancer mortality: the PLCO randomized trial (accessed 2026-10-18)
- Lancet Respiratory Medicine, 2024 — Chang GC et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan (TALENT) (accessed 2026-10-18)
- New England Journal of Medicine, 2017 — Chan KCA et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer (accessed 2026-10-18)